同: VM-26

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/08/24 12:54:14」(JST)

wiki en

Teniposide (Vumon, VM-26) is a chemotherapeutic medication^[1] mainly used in the treatment of childhood acute lymphocytic leukemia (ALL). It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body.

Mechanism of action

Teniposide causes dose-dependent single- and double-stranded breaks in DNA and DNA-protein cross-links. The mechanism of action appears to be related to the inhibition of type II topoisomerase activity since teniposide does not intercalate into DNA or bind strongly to DNA. The cytotoxic effects of teniposide are related to the relative number of double-stranded DNA breaks produced in cells, which are a reflection of the stabilization of a topoisomerase II-DNA intermediate.

Administration

The medication is injected though a vein and burns if it leaks under the skin. It is sometimes used in combination with other anticancer drugs.

Side-effects

Teniposide, when used with other chemotherapeutic agents for the treatment of ALL, results in severe myelosuppression. Other common side effects include gastrointestinal toxicity, hypersensitivity reactions, and alopecia.

References

^ Cragg, Gordon M.; Newman, David J. (2005). "Plants as a source of anti-cancer agents". Journal of Ethnopharmacology 100 (1–2): 72–9. doi:10.1016/j.jep.2005.05.011. PMID 16009521.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人におけるフィラデルフィア染色体陽性急性リンパ芽球性白血病に対する寛解後療法 post remission therapy for philadelphia chromosome positive acute lymphoblastic leukemia in adults
2. 高解像度食道内圧検査 high resolution manometry
3. 脳転移に対する全身療法 systemic therapy for brain metastases
4. 抗腫瘍療法関連肺毒性：細胞傷害性薬物 pulmonary toxicity associated with antineoplastic therapy cytotoxic agents
5. 成人における再発性および難治性の急性リンパ芽球性白血病の治療 treatment of relapsed or refractory acute lymphoblastic leukemia in adults

English Journal

Separating chemotherapy-related developmental neurotoxicity from cytotoxicity in monolayer and neurosphere cultures of human fetal brain cells.

Ivanov DP1, Al-Rubai AJ2, Grabowska AM3, Pratten MK4.
Toxicology in vitro : an international journal published in association with BIBRA.Toxicol In Vitro.2016 Dec;37:88-96. doi: 10.1016/j.tiv.2016.09.007. Epub 2016 Sep 10.
Chemotherapy-induced neurotoxicity can reduce the quality of life of patients by affecting their intelligence, senses and mobility. Ten percent of safety-related late-stage clinical failures are due to neurological side effects. Animal models are poor in predicting human neurotoxicity due to intersp
PMID 27622579

Preparation and evaluation of teniposide-loaded polymeric micelles for breast cancer therapy.

Chu B1, Shi S2, Li X2, Hu L3, Shi L3, Zhang H3, Xu Q3, Ye L3, Lin G3, Zhang N3, Zhang X4.
International journal of pharmaceutics.Int J Pharm.2016 Nov 20;513(1-2):118-129. doi: 10.1016/j.ijpharm.2016.09.005. Epub 2016 Sep 3.
Self-assembled polymeric micelles have been widely applied in anticancer drug delivery systems. Teniposide is a broad spectrum and effective anticancer drug, but its poor water-solubility and adverse effects of commercial formulation (VM-26) restrict its clinical application. In this work, teniposid
PMID 27596115

Biotechnological interventions for harnessing podophyllotoxin from plant and fungal species: current status, challenges, and opportunities for its commercialization.

Kumari A1,2, Singh D1, Kumar S1,2.
Critical reviews in biotechnology.Crit Rev Biotechnol.2016 Sep 20:1-15. [Epub ahead of print]
Podophyllotoxin is an aryltetralin lignan synthesized in several plant species, which is used in chemotherapies for cancers and tumor treatment. More potent semisynthetic derivatives of podophyllotoxin such as etoposide and teniposide are being developed and evaluated for their efficacy. To meet the
PMID 27644897

Japanese Journal

Improved high-performance liquid chromatographic analysis of teniposide in human plasma

Journal of chromatography. B, Biomedical sciences and applications 709(2), 315-319, 1998-05-29
NAID 10024528775

Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132 : involvement of NF-κB activation in drug resistance

Cancer Res. 58, 3059-3065, 1998
NAID 80010437447

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer

J Clin Oncol 16, 2133-2141, 1998
NAID 10010655353

Related Pictures

★リンクテーブル★

リンク元	「イリノテカン」「VM-26」「vumon」

「イリノテカン」

Teniposide
Systematic (IUPAC) name
	(5R,5aR,8aR,9S)-5,8,8a,9-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-({4,6-O-[(R)-2-thienylmethylene]-β-D-glucopyranosyl}oxy)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
Clinical data
AHFS/Drugs.com	monograph
MedlinePlus	a692045
Pregnancy; category	AU: D; US: D (Evidence of risk);
Legal status	US: ℞-only;
Routes of; administration	Intravenous
Pharmacokinetic data
Bioavailability	n/a
Protein binding	>99%
Metabolism	Hepatic (CYP2C19-mediated)
Biological half-life	5 hours
Excretion	Renal and fecal
Identifiers
CAS Registry Number	29767-20-2
ATC code	L01CB02
PubChem	CID: 34698
IUPHAR/BPS	6843
DrugBank	DB00444
ChemSpider	31930
UNII	957E6438QA
KEGG	D02698
ChEBI	CHEBI:75988
ChEMBL	CHEMBL1200536
Chemical data
Formula	C32H32O13S
Molecular mass	656.655 g/mol
(what is this?) (verify)